Jaguar Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 24, 2019, reports on the results of Jaguar Health, Inc.'s 2019 Annual Meeting of Stockholders and provides an update regarding the Company's listing status on The Nasdaq Capital Market. The Company is an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance and regulatory status. It does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Corporate Actions
- Stockholder Approvals: Six proposals were submitted and approved at the Annual Meeting:
- Election of three Class I directors (James J. Bochnowski, Lisa A. Conte, and Jonathan B. Siegel).
- Authorization for a reverse stock split of Common Stock at a ratio between 1-for-30 and 1-for-70, to be determined by the Board by November 3, 2019.
- Amendment to the 2014 Stock Incentive Plan to increase authorized shares to 12.5% of outstanding shares on a fully diluted basis, contingent on the reverse stock split.
- Approval for the issuance of shares upon exchange of promissory notes and exercise of warrants from private placements (Nasdaq Rule 5635).
- Approval for the issuance of shares upon exercise of a warrant related to a letter of credit cancellation (Nasdaq Rule 5635).
- Granting of discretionary authority to adjourn the meeting to solicit additional proxies if necessary.
- Nasdaq Delisting Notice: The Company received notice from Nasdaq Staff of potential delisting due to continued non-compliance with the minimum $1.00 bid price requirement (Rule 5550(a)(2)) as of May 8, 2019.
- Hearing Scheduled: The Company has requested a hearing before the Nasdaq Hearings Panel, scheduled for July 11, 2019, to request an extension to evidence compliance. Any delisting action is stayed pending the hearing outcome.
Outlook, Risks, and Contingencies
The Company intends to take definitive steps to evidence compliance with Nasdaq listing requirements, including the bid price rule. However, the filing explicitly states there is no assurance that the Panel will grant a request for continued listing, that the Company will meet the bid price requirement within any extension period, or that the reverse stock split will successfully resolve the compliance issue. The filing contains forward-looking statements regarding these efforts which involve significant risks and uncertainties.
Investor Verification Checklist
- Verify the exact reverse stock split ratio once announced by the Board (must be between 1-for-30 and 1-for-70).
- Monitor the outcome of the Nasdaq Hearings Panel hearing scheduled for July 11, 2019.
- Review the Company's subsequent filings for evidence of compliance with the $1.00 minimum bid price requirement.
- Confirm the impact of the approved stock incentive plan amendment on future dilution.